Basic information
The company's patent ductus arteriosus occluder and atrial defect occluder are one of the few occluder products that were first developed and produced in China. The research and development project was established in June 2003. The first trial production registrations were launched on December 27, 2004 and September 20, 2005. Both products were converted to quasi-production registrations on March 6, 2007. So far, more than ten products have been registered. Year. This laid a solid foundation and accumulated rich experience for us to develop ventricular septal defect occluders. In order to meet the needs of interventional treatment of ventricular septal defect, we developed a ventricular septal defect occluder based on the successful development of two previous occluder products.
The human ventricular septum refers to the septal tissue that separates the left and right ventricles. Depending on whether the ventricular septal defect occurs in the muscular part of the ventricular septum or the membranous part after the patient is born, it is also called muscular ventricular defect or membranous ventricular defect. Therefore, in order to meet the needs of interventional sealing treatment, ventricular septal defect sealing devices are also divided into two models: muscular and membranous. The product is woven from nickel-titanium alloy wire and is in the shape of a double-umbrella bottle plug, connected by a short waist. It is filled with PET polyester non-woven fabric and is used to treat ventricular septal defects.